Lifevantage (NASDAQ:LFVN) Releases Earnings Results, Misses Estimates By $0.04 EPS

Key Points

• LifeVantage reported a quarterly miss with $0.12 EPS vs. $0.16 expected and revenue of $43.7 million (down 25.2% YoY), and now expects fiscal 2026 results near the lower end of prior guidance.
• Despite pressure on profitability (gross margin fell to 79% and Q3 GAAP net income was $1.4 million), the company has a solid balance sheet with $12.5 million cash, no debt, an active $60 million buyback authorization (≈$59M remaining) and an 11% higher quarterly dividend of $0.05.
• Management is pursuing growth initiatives (Shopify e‑commerce upgrade, a 12‑month VIP bonus, new product launch and a U.S. patent) and leadership change (new CEO joining in August); the stock nevertheless rallied up 9.3% on heavy volume while insiders and institutions increased holdings.

Lifevantage (NASDAQ:LFVN - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.16 by ($0.04), FiscalAI reports. Lifevantage had a return on equity of 29.59% and a net margin of 3.74%.The business had revenue of $43.72 million during the quarter, compared to analyst estimates of $47.77 million.

Here are the key takeaways from Lifevantage's conference call:

• The company reported net revenue of $43.7 million, down 25.2% year‑over‑year, driven mainly by weaker sales of the MindBody GLP‑1 System and fewer active accounts, and now expects fiscal 2026 results near the lower end of prior guidance.
• Profitability pressures included a decline in gross margin to 79% (81% prior year) from higher shipping/warehouse costs and inventory obsolescence, with Q3 GAAP net income falling to $1.4 million ($0.11/share).
• Financial position remains solid with $12.5 million cash, no debt, $5.5 million of cash from operations year‑to‑date, an active share repurchase program (board authorized $60 million, ~$59 million remaining), and an 11% higher quarterly dividend of $0.05 per share.
• Management is pursuing strategic initiatives to boost growth, including an e‑commerce and back‑office upgrade via Shopify rollout later this year and a newly announced 12‑month VIP bonus incentive aimed at accelerating consultant growth and leadership development.
• Product and leadership catalysts include the U.S. patent for the Healthy Glow Essentials Stack, the October convention where a new product launch is planned, the LoveBiome/P84 additions to the portfolio, and the appointment of Terrence Moorehead as CEO joining in August.

Lifevantage Stock Up 9.3%

Shares of Lifevantage stock traded up $0.51 during trading hours on Wednesday, hitting $6.00. 814,778 shares of the company's stock traded hands, compared to its average volume of 214,839. Lifevantage has a twelve month low of $3.90 and a twelve month high of $15.00. The company has a market cap of $76.86 million, a PE ratio of 10.00 and a beta of 0.52. The stock has a 50 day simple moving average of $4.70 and a 200-day simple moving average of $5.81.

Insider Buying and Selling

In other Lifevantage news, Director Judd Dayton acquired 18,097 shares of the stock in a transaction on Friday, February 27th. The stock was purchased at an average price of $4.63 per share, for a total transaction of $83,789.11. Following the purchase, the director directly owned 69,859 shares in the company, valued at $323,447.17. This trade represents a 34.96% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders bought a total of 38,207 shares of company stock valued at $178,585 over the last ninety days. Corporate insiders own 21.95% of the company's stock.

Institutional Trading of Lifevantage

A number of hedge funds and other institutional investors have recently made changes to their positions in LFVN. Goldman Sachs Group Inc. boosted its stake in Lifevantage by 305.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 200,222 shares of the company's stock valued at $1,233,000 after acquiring an additional 150,785 shares during the last quarter. Geode Capital Management LLC increased its holdings in Lifevantage by 106.1% in the second quarter. Geode Capital Management LLC now owns 245,332 shares of the company's stock valued at $3,210,000 after buying an additional 126,274 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Lifevantage by 8.3% during the 4th quarter. Renaissance Technologies LLC now owns 922,918 shares of the company's stock worth $5,685,000 after buying an additional 70,900 shares during the last quarter. Advyzon Investment Management LLC grew its position in shares of Lifevantage by 346.3% in the 4th quarter. Advyzon Investment Management LLC now owns 62,277 shares of the company's stock worth $384,000 after acquiring an additional 48,322 shares in the last quarter. Finally, Walleye Capital LLC bought a new stake in shares of Lifevantage in the 4th quarter valued at approximately $289,000. Institutional investors own 35.32% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Weiss Ratings lowered Lifevantage from a "hold (c)" rating to a "hold (c-)" rating in a research note on Monday. Lake Street Capital reaffirmed a "buy" rating on shares of Lifevantage in a research report on Thursday, February 5th. Finally, Loop Capital set a $5.00 price objective on Lifevantage in a research note on Thursday, February 5th. One investment analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $5.00.

Lifevantage Company Profile

LifeVantage Corporation is a publicly traded company that develops, markets and distributes nutritional supplements, skincare products and weight-management solutions through a direct-selling business model. The company's flagship offering, Protandim®, is formulated to activate the Nrf2 pathway, which is associated with cellular defense processes. LifeVantage also markets the PhysIQ® line for metabolism and body composition support and the TrueScience® skincare regimen, targeting a range of health and wellness needs.

Founded in 1999 and headquartered in Sandy, Utah, LifeVantage combines research in nutrigenomics with a network of independent distributors to bring its products to market.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.